Pharmaceuticals

NHWA

NHWA released FY2026 Q1 earnings on April 17 Pre-Market (BJT), actual revenue CNY 1.61 B (forecast CNY 1.703 B), actual EPS CNY 0.31 (forecast CNY 0.47)

NHWA released FY2025 Q4 earnings on April 17 After-Market (BJT), actual revenue CNY 1.44 B (forecast CNY 1.631 B), actual EPS CNY -0.0495 (forecast CNY 0.21)

NHWA released FY2025 Annual Earnings on April 17 After-Market (BJT), actual revenue CNY 5.911 B (forecast CNY 6.131 B), actual EPS CNY 1.05 (forecast CNY 1.2766)

NHWA to Release FY2025 Annual Earnings on April 18 After-Market (BJT), Forecast Revenue CNY 6.131 B, EPS CNY 1.2766

NHWA to Release FY2026 Q1 Earnings on April 18 Pre-Market (BJT), Forecast Revenue CNY 1.703 B, EPS CNY 0.47

NHWA released FY2025 Q3 earnings on October 24 After-Market (BJT), actual revenue CNY 1.461 B (forecast CNY 1.57 B), actual EPS CNY 0.4 (forecast CNY 0.42)

NHWA released FY2025 9 Months earnings on October 24 After-Market (BJT), actual revenue CNY 4.471 B, actual EPS CNY 1.0889

NHWA to Release FY2025 Q3 Earnings on October 25 After-Market (BJT), Forecast Revenue CNY 1.57 B, EPS CNY 0.42

Evan Pharma's Drug NH600001 Raw Material Listing Application Accepted

NHWA released FY2025 Q2 earnings on July 29 Pre-Market (BJT), actual revenue CNY 1.499 B (forecast CNY 1.631 B), actual EPS CNY 0.3888 (forecast CNY 0.39)

NHWA released FY2025 Semi-Annual Earnings on July 29 Pre-Market (BJT), actual revenue CNY 3.01 B, actual EPS CNY 0

NHWA FY2025 Semi-Annual Earning Release on July 30, 2025 (BJT)

Enhua Pharmaceutical Updates ESG Rating

Enhua Pharmaceutical Responds to Impact of National Drug Concentration Procurement on Profits

Chairman Sun of Enerway Added Shares

EHN Healthcare Explains Stock Incentive Plan Unfreeze Conditions

Enhua Pharmaceutical Responds to Etomidate Tender

Eunah Pharmaceutical Receives Approval for Clinical Trials of NH104 for Insomnia and Depression-Related Insomnia

Eonlab acquires new patent authorization

Fentanyl Producers Respond to US Tariff Hikes

Ordinary dividend (cash)

Ex Date: 2026.05.26, Cash dividend 0.4 CNY

002262

According to the Zhitong Finance APP, NHWA released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 4.471 billion yuan, a year-on-year increase of 7.85%. The net profit attributable to shareholders of the listed company was 1.106 billion yuan, a year-on-year increase of 8.42%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 1.109 billion yuan, a year-on-year increase of 7.59%

Zhitong

NHWA released its performance for the first three quarters, with a net profit attributable to the parent company of 1.106 billion yuan, a year-on-year increase of 8.42%

According to the Zhitong Finance APP, NHWA announced that the company recently obtained the "Drug Registration Certificate" for the chemical drug Tapentadol Hydrochloride Tablets issued by the National Medical Products Administration. Tapentadol Hydrochloride Tablets are used for the treatment of acute pain in adult patients that is severe enough to require the use of opioid analgesics, as well as for acute pain that cannot be adequately relieved by alternative treatments

NHWA: The hydrochloride of Tizanidine tablets has obtained a drug registration certificate

603127

06127

000813

603590

688091

300363

Innovative drug concept stocks fluctuated and rose sharply, DEZHAN HEALTHCARE hit the limit up, Porton, JOINN, NHWA, Konruns, and SHANGHAI YIZHONG followed suit

JOINN

DEZHAN HEALTHCARE

Konruns

SHANGHAI YIZHONG

Porton

Innovative drug concept stocks fluctuate and rise, DEZHAN HEALTHCARE hits the limit up

According to the Qichacha APP, recently, Xuzhou Aizhi Jia Pet Supplies Co., Ltd. was established with a registered capital of 1 million yuan. The business scope includes: internet information services; road cargo transportation; food sales; food internet sales; veterinary drug operations, etc. Qichacha's equity penetration shows that the company is wholly owned by Xuzhou NHWA Unified Pharmaceutical Chain Sales Co., Ltd., a subsidiary of NHWA

NHWA Investment establishes a pet supplies company

NHWA released its semi-annual report for 2025, with operating revenue of 3.01 billion yuan, a year-on-year increase of 8.93%; net profit attributable to the parent company was 700 million yuan, a year-on-year increase of 11.38%. The net profit excluding non-recurring gains and losses was 699 million yuan, an increase of 10.33%. The basic earnings per share were 0.69 yuan. The company has over 70 research projects underway, with research funding of 395 million yuan, an increase of 23.97%. In terms of innovative drug research and development, among the 17 projects under research, 1 has completed phase III clinical trials, and 2 have completed phase II clinical trials. In the field of generic drugs, 48 projects are underway, with 1 production approval obtained

NHWA released its performance for the first half of the year, with a net profit attributable to the parent company of 700 million yuan, an increase of 11.38%

According to the Zhitong Finance APP, NHWA announced that the company's chairman, Mr. Sun Pengsheng, increased his holdings of the company's A-shares by 237,900 shares through centralized bidding on June 16, 2025

NHWA's chairman Sun Pengsheng increased his holdings by 237,900 shares

688513

Recently, Chengdu EASTON BIOPHARMACEUTICALS Co., Ltd. officially received approval for the listing of Oxazepam Tablets. Jiangsu NHWA Pharmaceutical Co., Ltd. has reached an exclusive commercialization cooperation with EASTON BIOPHARMACEUTICALS for this product. NHWA Pharmaceutical will accelerate the market expansion and clinical application of Oxazepam Tablets

EASTON BIOPHARMACEUTICALS

NHWA and EASTON BIOPHARMACEUTICALS have reached a strategic cooperation

According to the Zhitong Finance APP, NHWA announced that the company recently received the "Drug Clinical Trial Approval Notice" for two specifications of the Class 1 chemical drug NH104 from the National Medical Products Administration, and will soon commence clinical trials. The announcement stated that NH104 is a new generation innovative drug for the treatment of insomnia and depression accompanied by insomnia. Preclinical trial results indicate that it has strong anti-insomnia and adjunctive antidepressant efficacy, with good safety and pharmacokinetic characteristics

NHWA: Clinical trial for NH104 tablets approved

On May 15th, NHWA stated on the interactive platform that the innovative drug NH600001 emulsion injection developed by the company has completed Phase III clinical trials and is expected to file for NDA this year, aiming to achieve market launch as soon as possible

NHWA: The innovative drug NH600001 emulsion injection is expected to file for NDA this year

NHWA(002262.SZ)